228 related articles for article (PubMed ID: 28379307)
1. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Jain P; Aoki E; Keating M; Wierda WG; O'Brien S; Gonzalez GN; Ferrajoli A; Jain N; Thompson PA; Jabbour E; Kanagal-Shamanna R; Pierce S; Alousi A; Hosing C; Khouri I; Estrov Z; Cortes J; Kantarjian H; Ravandi F; Kadia TM
Ann Oncol; 2017 Jul; 28(7):1554-1559. PubMed ID: 28379307
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
[TBL] [Abstract][Full Text] [Related]
3. Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.
Rose A; Zhang L; Jain AG; Poovathukaran Babu A; Sokol L; Saeed H; Mo Q; Fan W; Zhang X
Am J Hematol; 2023 Jun; 98(6):913-921. PubMed ID: 36964941
[TBL] [Abstract][Full Text] [Related]
4. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
Hopfinger G; Busch R; Pflug N; Weit N; Westermann A; Fink AM; Cramer P; Reinart N; Winkler D; Fingerle-Rowson G; Stilgenbauer S; Döhner H; Kandler G; Eichhorst B; Hallek M; Herling M
Cancer; 2013 Jun; 119(12):2258-67. PubMed ID: 23512246
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
Hu Z; Medeiros LJ; Fang L; Sun Y; Tang Z; Tang G; Sun T; Quesada AE; Hu S; Wang SA; Pei L; Lu X
Am J Hematol; 2017 May; 92(5):441-447. PubMed ID: 28194886
[TBL] [Abstract][Full Text] [Related]
6. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC).
Guillaume T; Beguin Y; Tabrizi R; Nguyen S; Blaise D; Deconinck E; Redjoul R; Cornillon J; Guillerm G; Contentin N; Sirvent A; Turlure P; Salmon A; Huynh A; François S; Peffault de Latour R; Yakoub-Agha I; Mohty M
Eur J Haematol; 2015 Mar; 94(3):265-9. PubMed ID: 25130897
[TBL] [Abstract][Full Text] [Related]
8. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
9. Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.
Yamasaki S; Nitta H; Kondo E; Uchida N; Miyazaki T; Ishiyama K; Kiyota M; Matsuoka H; Ichinohe T; Fukuda T; Atsuta Y; Suzumiya J; Suzuki R
Ann Hematol; 2019 Sep; 98(9):2213-2220. PubMed ID: 31327025
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.
Murthy HS; Ahn KW; Estrada-Merly N; Alkhateeb HB; Bal S; Kharfan-Dabaja MA; Dholaria B; Foss F; Gowda L; Jagadeesh D; Sauter C; Abid MB; Aljurf M; Awan FT; Bacher U; Badawy SM; Battiwalla M; Bredeson C; Cerny J; Chhabra S; Deol A; Diaz MA; Farhadfar N; Freytes C; Gajewski J; Gandhi MJ; Ganguly S; Grunwald MR; Halter J; Hashmi S; Hildebrandt GC; Inamoto Y; Jimenez-Jimenez AM; Kalaycio M; Kamble R; Krem MM; Lazarus HM; Lazaryan A; Maakaron J; Munshi PN; Munker R; Nazha A; Nishihori T; Oluwole OO; Ortí G; Pan DC; Patel SS; Pawarode A; Rizzieri D; Saba NS; Savani B; Seo S; Ustun C; van der Poel M; Verdonck LF; Wagner JL; Wirk B; Oran B; Nakamura R; Scott B; Saber W
Transplant Cell Ther; 2022 Apr; 28(4):187.e1-187.e10. PubMed ID: 35081472
[TBL] [Abstract][Full Text] [Related]
11. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
Hu Z; Li S; Medeiros LJ; Sun T
Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
[TBL] [Abstract][Full Text] [Related]
12. New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.
Pflug N; Cramer P; Robrecht S; Bahlo J; Westermann A; Fink AM; Schrader A; Mayer P; Oberbeck S; Seiler T; Zenz T; Dürig J; Kreuzer KA; Stilgenbauer S; Eichhorst B; Hallek M; Herling M; Hopfinger G
Leuk Lymphoma; 2019 Mar; 60(3):649-657. PubMed ID: 30234404
[TBL] [Abstract][Full Text] [Related]
13. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract][Full Text] [Related]
14. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
Cao TM; Coutre SE
Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
16. Recurrence of T-Cell Prolymphocytic Leukemia With a Rare Presentation as Diffuse Generalized Skin Lesion.
Wasifuddin M; Sabzposh H; Sun L; Wu R; Wang JC
J Investig Med High Impact Case Rep; 2023; 11():23247096231176223. PubMed ID: 37219076
[TBL] [Abstract][Full Text] [Related]
17. T-cell Prolymphocytic Leukemia.
Sud A; Dearden C
Hematol Oncol Clin North Am; 2017 Apr; 31(2):273-283. PubMed ID: 28340878
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.
Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
[TBL] [Abstract][Full Text] [Related]
19. Advances and Perspectives in the Treatment of T-PLL.
Braun T; von Jan J; Wahnschaffe L; Herling M
Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
[TBL] [Abstract][Full Text] [Related]
20. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
